Nantahala Capital Management LLC Takes $19.01 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX

Nantahala Capital Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,901,160 shares of the biotechnology company’s stock, valued at approximately $19,011,600. Nantahala Capital Management LLC owned 0.74% of BioCryst Pharmaceuticals as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth about $238,930,000. Vanguard Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock worth $173,732,000 after buying an additional 482,494 shares during the last quarter. RA Capital Management L.P. bought a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $123,452,000. Deerfield Management Company L.P. lifted its holdings in BioCryst Pharmaceuticals by 159.4% in the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after buying an additional 7,477,000 shares during the period. Finally, State Street Corp lifted its holdings in BioCryst Pharmaceuticals by 12.9% in the fourth quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock valued at $86,371,000 after buying an additional 1,265,773 shares during the period. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 0.5%

BCRX stock opened at $9.82 on Friday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.22. The firm has a market cap of $2.51 billion, a PE ratio of -6.55 and a beta of 0.55. The business’s 50-day moving average price is $9.71 and its two-hundred day moving average price is $9.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The company had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. During the same quarter last year, the firm posted $0.15 earnings per share. BioCryst Pharmaceuticals’s revenue was up 33.6% compared to the same quarter last year. On average, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current year.

Analyst Ratings Changes

BCRX has been the subject of a number of analyst reports. Needham & Company LLC lowered their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Royal Bank Of Canada reduced their price target on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. JPMorgan Chase & Co. began coverage on BioCryst Pharmaceuticals in a report on Monday, July 13th. They issued a “neutral” rating and a $12.00 price objective for the company. Finally, Cantor Fitzgerald increased their target price on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.60.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.